Search

Search Constraints

You searched for: Author/Creator Keating, M.-M.

Search Results

1. P573: PHARMACOKINETIC EXPOSURE EQUIVALENCE AND PRELIMINARY EFFICACY AND SAFETY FROM A RANDOMIZED CROSS OVER PHASE 3 STUDY OF AN ORAL HYPOMETHYLATING AGENT DEC-C COMPARED TO IV DECITABINE IN AML PATIENTS. (23rd June 2022)

2. S158: FINAL RESULT OF TKI DISCONTINUATION TRIAL WITH DASATINIB FOR SECOND ATTEMPT OF TREATMENT FREE REMISSION AFTER FAILING FIRST ATTEMPT WITH IMATINIB: TREATMENT-FREE REMISSION ACCOMPLISHED BY DASATINIB. (23rd June 2022)

3. Topic: AS02-Epidemiology: EVALUATION OF INFECTIOUS COMPLICATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A PROSPECTIVE COHORT STUDY FROM THE CANADIAN MDS REGISTRY. (May 2023)

4. Topic: AS02-Epidemiology: THE IMPACT OF GAINING OR LOSING TRANSFUSION INDEPENDENCE ON QUALITY OF LIFE IN MYELODYSPLASTIC SYNDROMES. (September 2021)

5. Topic: AS08-Treatment/AS08a-Current treatment options - Hypomethylating agents: PROLONGED SURVIVAL OBSERVED IN 133 MDS PATIENTS TREATED WITH ORAL DECITABINE/CEDAZURIDINE. (September 2021)

6. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES. (May 2023)

7. Topic: AS08-Treatment/AS08j-Supportive care - Iron overload: MDS IRON ROAD: AN INTERNET-BASED ALGORITHM FOR THE DIAGNOSIS, WORKUP AND MANAGEMENT OF IRON OVERLOAD IN MDS FROM THE CANADIAN CONSORTIUM ON MDS (CCMDS). (September 2021)